Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.53 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.52 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.49 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.48 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | F7 | P08709 | 1/20 | 0.46 |
| ▸ | F3 | P13726 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12359372 | 0.86 | HTT (0.53) | HTTKMT2AHCRTR1HCRTR2TP53 | |
| SCHEMBL12391556 | 0.85 | CYP2A6 (0.48) | HTTKMT2AP2RX7MKNK1MKNK2 | |
| SCHEMBL12391550 | 0.85 | MKNK1 (0.54) | P2RX7MKNK1MKNK2ABL1SLC2A1 | |
| SCHEMBL12024786 | 0.81 | HCRTR1 (0.54) | HCRTR1HCRTR2 | |
| SCHEMBL10134750 | 0.79 | HCRTR1 (0.50) | HTTKMT2AHCRTR1HCRTR2TP53 | |
| SCHEMBL13443055 | 0.79 | HCRTR1 (0.57) | HCRTR1HCRTR2 | |
| SCHEMBL12024774 | 0.79 | PDE2A (0.49) | P2RX7MKNK1MKNK2HCRTR1HCRTR2 | |
| SCHEMBL12359373 | 0.79 | POLQ (0.47) | HTTKMT2AMKNK1MKNK2HCRTR1 | |
| SCHEMBL13498677 | 0.78 | HCRTR2 (0.51) | HCRTR1HCRTR2 | |
| SCHEMBL13626336 | 0.78 | KMO (0.61) | KMT2AMKNK1MKNK2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399494-B2 | 2,5-disubstituted phenyl carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20110207747-A1 | 2,5-Disubstituted Phenyl Carboxamide Orexin Receptor Antagonists | MERCK & CO., INC. | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207747-A1 | 2,5-Disubstituted Phenyl Carboxamide Orexin Receptor Antagonists | HCRTR2, HCRTR1, CRHR2 | HTT 192/4885KMT2A 646/4885P2RX7 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.